Abstract 466: Combined Telmisartan and Amlodipine Reduces Albuminuria via Reduction in Renal Inflammation in Animal Model of Metabolic Syndrome
The utilization of combined Telmisartan (T) and amlodipine (A) is well established in management of Hypertension. However, it is not known if this combination would be beneficial in metabolic syndrome (MS). We hypothesized that combined T+A decreases albuminuria in obese Zucker (OZ) rats, a model of MS, via reduction of renal inflammation. Studies were conducted in lean Zucker (LZ) and OZ rats fed high fat diet and treated for 6 wks with oral administration of vehicle (V), T (3mg/kg/d), or A (10mg/kg/d) individually and combined. We monitored changes in body weight (BW), systolic BP (SBP), 24h UV, fasting blood glucose (FBG), urine albumin/creatinine ratio (UACR), urine aldosterone/creatinine ratio (UaldoCR), and renal interstitial fluid (RIF) recovery rate of nitric oxide (NO), IL-6 and TNFα. Data are shown (Table) as mean±SE. *p<0.01 vs ZL, +p<0.01 vs ZO+V, #p<0.01 vs ZO+T or ZO+A. Different treatments did not cause significant changes in BW, FBG or UV. These results demonstrate that T, A or their combination reduce albuminuria in a model of metabolic syndrome via reduction in renal inflammation. In addition to SBP reduction, combined T and A have more favorable renal effects than either individual treatment.
- © 2012 by American Heart Association, Inc.